Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CNR2 | P34972 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2276927 | 0.87 | SMN1; SMN2 (0.51) | LMNAALDH1A1CNR2RAB9AGRM5 | |
| SCHEMBL2222573 | 0.87 | RAB9A (0.48) | LMNAALDH1A1CNR2RAB9AGRM5 | |
| SCHEMBL12516066 | 0.87 | LMNA (0.46) | LMNAALDH1A1CNR2RAB9AGRM5 | |
| SCHEMBL9960850 | 0.82 | GRM5 (0.50) | LMNAALDH1A1RAB9AGRM5SMN1; SMN2 | |
| SCHEMBL12516065 | 0.79 | HSD11B1 (0.39) | LMNAALDH1A1CNR2RAB9AGRM5 | |
| SCHEMBL6085762 | 0.76 | NPC1 (0.57) | LMNAALDH1A1CNR2RAB9ASMN1; SMN2 | |
| SCHEMBL2221951 | 0.76 | GRM5 (0.73) | CNR2GRM5P2RX7MEN1KMT2A | |
| SCHEMBL30794648 | 0.76 | GRM5 (0.73) | CNR2GRM5P2RX7MEN1KMT2A | |
| SCHEMBL3328525 | 0.76 | SMN1; SMN2 (0.54) | ALDH1A1RAB9AGRM5SMN1; SMN2NPC1 | |
| Hydrochloric Acid SCHEMBL6086630 | 0.75 | NPC1 (0.56) | LMNAALDH1A1CNR2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20100120789-A1 | Compound | STERIX LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | STERIX LIMITED (GB) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042929-A1 | 11-Beta-Hydroxysteroid Dehydrogenase Inhibitors | HSD3B1, HSD3B2, HSD11B1 | LMNA 4234/4885ALDH1A1 437/4885CNR2 927/4885 |
| US-20100120789-A1 | Compound | NR0B2, NR0B1, NR4A1 | LMNA 4234/4885ALDH1A1 3143/4885CNR2 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.